Publications by authors named "Martina M Owens"

Background: The widespread clinical application of genome-wide sequencing has resulted in many new diagnoses for rare genetic conditions, but testing regularly identifies variants of uncertain significance (VUS). The remarkable rise in the amount of genomic data has been paralleled by a rise in the number of protein structures that are now publicly available, which may have clinical utility for the interpretation of missense and in-frame insertions or deletions.

Methods: Within a UK National Health Service genomic medicine diagnostic laboratory, we investigated the number of VUS over a 5-year period that were evaluated using protein structural analysis and how often this analysis aided variant classification.

View Article and Find Full Text PDF

Rapid advances in sequencing technology have led to significant improvements in genomic analysis, resulting in increased understanding of the molecular basis of many endocrine conditions. Genomic testing for rare disease is being integrated into everyday clinical practice, as the importance of confirming a genetic diagnosis earlier in a patient's pathway helps direct their clinical care and specialized management. In England, the new nationally commissioned Genomic Medicine Service has started to deliver testing for rare and inherited disease and cancer somatic tissue via seven Genomic Laboratory Hubs.

View Article and Find Full Text PDF

Despite the rapid expansion in recent years of databases reporting either benign or pathogenic genetic variations, the interpretation of novel missense variants remains challenging, particularly for clinical or genetic testing laboratories where functional analysis is often unfeasible. Previous studies have shown that thermodynamic analysis of protein structure can discriminate between groups of benign and pathogenic missense variants. However, although structures exist for many human diseaseā€’associated proteins, such analysis remains largely unexploited in clinical laboratories.

View Article and Find Full Text PDF

We report 15 individuals with de novo pathogenic variants in WDR26. Eleven of the individuals carry loss-of-function mutations, and four harbor missense substitutions. These 15 individuals comprise ten females and five males, and all have intellectual disability with delayed speech, a history of febrile and/or non-febrile seizures, and a wide-based, spastic, and/or stiff-legged gait.

View Article and Find Full Text PDF
Article Synopsis
  • Long-read sequencing technologies from PacBio and ONT allow for the phasing of mutations that are located several kilobases apart, which is important for understanding genetic variations.
  • The study utilized long-range PCR combined with ONT and PacBio sequencing to successfully phase two variants in the RET gene that are 9 kb apart and re-evaluated existing data on other important haplotypes.
  • The researchers identified potential methodological issues, such as PCR-chimera formation and reference alignment bias, that could compromise the accuracy of phasing variants using these advanced sequencing techniques.
View Article and Find Full Text PDF
Article Synopsis
  • - The study aimed to compare different methods for detecting EGFR mutations in tumor samples from patients with non-small cell lung cancer, as these mutations help predict responses to specific treatments.
  • - Eleven laboratories tested coded samples with mutation levels ranging from 0% to 15%, focusing on two key mutations, p.L858R and c.2235_2249del, which are common in about 90% of mutation-positive cases.
  • - Results showed that various techniques like Sanger sequencing and pyrosequencing had better sensitivity than previously reported levels, with a 96% detection rate for samples containing at least 5% mutated DNA, indicating that multiple testing methods are effective for identifying EGFR mutations.
View Article and Find Full Text PDF